TY - JOUR
T1 - Prognostic Validation Using GesEPOC 2017 Severity Criteria
AU - Cabrera López, Carlos
AU - Casanova Macario, Ciro
AU - Marín Trigo, José María
AU - de-Torres, Juan P.
AU - Torres, Rebeca Sicilia
AU - González, Jesús María
AU - Polverino, Francesca
AU - Divo, Miguel
AU - Pinto Plata, Víctor
AU - Zulueta, Javier
AU - Callejas, Francisco Javier
AU - Celli, Bartolomé
N1 - Publisher Copyright:
Copyright © 2018 SEPAR. Publicado por Elsevier España, S.L.U. All rights reserved.
PY - 2019/8/1
Y1 - 2019/8/1
N2 - INTRODUCTION: The Spanish COPD guidelines (GesEPOC) have been recently modified. The aim of this study is to assess this revision and evaluate the prognosis of patients according to the new classification of severity. METHODS: A total of 700 COPD patients (83.9% men) were prospectively followed up for a mean period of 5 years in tertiary hospitals in Spain and the USA. Anthropometric data, lung function tests, dyspnea (according to the mMRC scale), BODE and Charlson index were collected. We calculated mortality at 5 years following the risk criteria proposed by the new GesEPOC. RESULTS: Mean age was 66±9.6 years and mean FEV1% was 59.7±20.2. The proportion of patients in the low-risk group was 40.43%. Patients in the high-risk group had a significantly higher BODE index than those in the low-risk group (2.92±0,66 vs. 0.52±1.91, p<0.001), while the Charlson index score was similar in both groups. Mortality at 60 months was significantly higher in the high-risk group (31.7% vs. 15.5%, p<0.001). Dyspnea and FEV1% were also independent predictors of mortality (p<0.001), and neither was inferior to the risk classification proposed by GesEPOC. CONCLUSIONS: The new severity index proposed by GesEPOC accurately predicts 5-year mortality. However, dyspnea and FEV1% have the same strength in predicting mortality.
AB - INTRODUCTION: The Spanish COPD guidelines (GesEPOC) have been recently modified. The aim of this study is to assess this revision and evaluate the prognosis of patients according to the new classification of severity. METHODS: A total of 700 COPD patients (83.9% men) were prospectively followed up for a mean period of 5 years in tertiary hospitals in Spain and the USA. Anthropometric data, lung function tests, dyspnea (according to the mMRC scale), BODE and Charlson index were collected. We calculated mortality at 5 years following the risk criteria proposed by the new GesEPOC. RESULTS: Mean age was 66±9.6 years and mean FEV1% was 59.7±20.2. The proportion of patients in the low-risk group was 40.43%. Patients in the high-risk group had a significantly higher BODE index than those in the low-risk group (2.92±0,66 vs. 0.52±1.91, p<0.001), while the Charlson index score was similar in both groups. Mortality at 60 months was significantly higher in the high-risk group (31.7% vs. 15.5%, p<0.001). Dyspnea and FEV1% were also independent predictors of mortality (p<0.001), and neither was inferior to the risk classification proposed by GesEPOC. CONCLUSIONS: The new severity index proposed by GesEPOC accurately predicts 5-year mortality. However, dyspnea and FEV1% have the same strength in predicting mortality.
KW - COPD
KW - EPOC
KW - GesEPOC
KW - Mortalidad
KW - Mortality
KW - Prognosis
KW - Pronóstico
KW - Riesgo
KW - Risk
UR - http://www.scopus.com/inward/record.url?scp=85060860407&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85060860407&partnerID=8YFLogxK
U2 - 10.1016/j.arbres.2018.12.002
DO - 10.1016/j.arbres.2018.12.002
M3 - Article
C2 - 30718019
AN - SCOPUS:85060860407
SN - 0300-2896
VL - 55
SP - 409
EP - 413
JO - Archivos de Bronconeumologia
JF - Archivos de Bronconeumologia
IS - 8
ER -